Sign in Subscribe
Machine learning

ARCHIMED Acquires Majority Stake in Arkstone Medical Solutions

Strategic Insights

— 1 min read

ARCHIMED, a leading investment firm focused exclusively on healthcare industries, has acquired a majority stake in Arkstone Medical Solutions (Arkstone), a pioneer in infectious disease clinical guidance and antimicrobial stewardship based on machine learning and generative artificial intelligence. The acquisition reflects ARCHIMED's ability to respond to public health issues, aligning with its strategic goals in the Healthcare IT and Diagnostics sectors. Arkstone's flagship product, OneChoice Report, leverages machine learning and generative AI to provide optimal infectious disease treatment recommendations.

Key Takeaways:

  • Arkstone's OneChoice Report is used by over 150 laboratories across the US and internationally, transforming how healthcare providers diagnose and treat infectious diseases.
  • Arkstone was founded in 2018 by three co-founders with backgrounds in software, clinical content, and customer operations.
  • The company provides Clinical Decision Support powered by Machine Learning (ML) and generative Artificial Intelligence (gen AI), helping healthcare providers optimize antimicrobial use.
  • ARCHIMED will work with Arkstone's management to accelerate the company's development through its MedValue playbook.
  • This is ARCHIMED's third investment in the MED Rise fund, following SeqCenter (Diagnostics) and FIM Medical (Medtech).
  • Arkstone represents a priority sub-sector identified through ARCHIMED's MedSeg tool and was sourced directly by the team through its MedDiscover approach.
  • This transaction marks a transformative milestone for Arkstone, enabling it to innovate and bring life-saving antimicrobial stewardship solutions to a broader global audience.

Statistics:

  • Over 150 laboratories across the US and internationally use Arkstone's OneChoice Report.
  • Arkstone was founded in 2018.
  • ARCHIMED manages €8 billion across its various funds.
  • The MED Rise fund has a €10 million to €1 billion investment range.
  • ARCHIMED has a top decile performance, especially from a DPI perspective, and was ranked as the world's 6th best performing Buyout firm in the 2023 HEC-DowJones ranking.

Sources:

  • ARCHIMED
  • PitchBook
  • HEC-DowJones ranking

Read more